Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.60 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1384473 | 0.88 | TSHR (0.61) | KDM4EBCHETP53SMN1; SMN2TSHR | |
| SCHEMBL2584080 | 0.86 | TSHR (0.61) | KDM4EBCHETP53SMN1; SMN2TSHR | |
| SCHEMBL1386316 | 0.86 | BCHE (0.68) | KDM4EBCHETP53SMN1; SMN2TSHR | |
| SCHEMBL1385703 | 0.85 | TSHR (0.68) | KDM4EBCHETP53SMN1; SMN2TSHR | |
| SCHEMBL11890502 | 0.84 | KDM4E (0.73) | KDM4EBCHETP53SMN1; SMN2TSHR | |
| SCHEMBL1387066 | 0.82 | KDM4E (0.80) | KDM4ETSHRHTTLMNA | |
| SCHEMBL2579670 | 0.81 | KDM4E (0.66) | KDM4EBCHETP53TSHR | |
| SCHEMBL1386481 | 0.81 | KDM4E (0.71) | KDM4EBCHETP53SMN1; SMN2TSHR | |
| SCHEMBL1387031 | 0.81 | KDM4E (0.74) | KDM4ETP53SMN1; SMN2TSHRHTT | |
| SCHEMBL1385523 | 0.81 | KDM4E (0.71) | KDM4EBCHETP53SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42890-E1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7385061-B2 | 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2008-06-10 | — | — | US | disclosed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | disclosed |
| EP-1636215-A1 | FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004103994-A1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043061-A1 | Furazanobenzimidazoles | FOXO1, CYP2F1, OXER1 | KDM4E 1039/4885BCHE 3544/4885TP53 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.